O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 8.5 GBX
Market Cap: £44.1m

Operating Margin

-2 039.8%
Current
Improving
by 681.1%
vs 3-y average of -2 720.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 039.8%
=
Operating Income
CA$-24.1m
/
Revenue
CA$2.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 039.8%
=
Operating Income
GBX-24.1m
/
Revenue
CA$2.2m

Peer Comparison

Country Company Market Cap Operating
Margin
CA
Ondine Biomedical Inc
LSE:OBI
44.1m GBP
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
188.6B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
186.9B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
138.7B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.1B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
130.7B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.5B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.9B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.5B USD
Loading...

Market Distribution

Lower than 92% of companies in Canada
Percentile
8th
Based on 4 855 companies
8th percentile
-2 039.8%
Low
-4 710 029.9% — -65.8%
Typical Range
-65.8% — 11%
High
11% — 71 100%
Distribution Statistics
Canada
Min -4 710 029.9%
30th Percentile -65.8%
Median -2.4%
70th Percentile 11%
Max 71 100%

Ondine Biomedical Inc
Glance View

Market Cap
44.1m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 039.8%
=
Operating Income
CA$-24.1m
/
Revenue
CA$2.2m
What is Ondine Biomedical Inc's current Operating Margin?

The current Operating Margin for Ondine Biomedical Inc is -2 039.8%, which is above its 3-year median of -2 720.9%.

How has Operating Margin changed over time?

Over the last 3 years, Ondine Biomedical Inc’s Operating Margin has increased from -9 703.5% to -2 039.8%. During this period, it reached a low of -9 703.5% on May 30, 2022 and a high of -1 545.7% on Jun 30, 2024.

Back to Top